Comprehensive Metabolic Panel (CMP) Testing Market Competitive Analysis

0
313
Comprehensive Metabolic Panel Testing
Comprehensive metabolic panel - laboratory analysis performed on a blood sample that is extracted from a vein in the arm using a hypodermic needle and vacutainer.

Analysts of Acumen Research predict the growth of the Comprehensive Metabolic Panel (CMP) Testing Market in the Healthcare industry by an average of 7.0% by 2026 and the market is projected to reach over USD 18,380 million during the forthcoming years.

The Comprehensive Metabolic Panel (CMP) is a commonly ordered set of 14 tests that give doctor a significant data about the present status of kidneys, electrolyte, liver and acid / base balance as well as blood sugar and blood proteins. Abnormal findings, and in particular abnormal results combinations, may show an issue that needs to be resolved. The CMP is used as a wide screening instrument for diabetes, liver illness, and kidney disease conditions. It is also used for monitoring disease complications or side effects of drugs used for disease treatment. The CMP is regularly provided for a medical or annual physical examination as part of a blood work-up and is gathered by inserting a needle into arm’s vein.

Request Free Sample Report Pages for Better Understanding, Download Here

North America has driven the market in 2018, due to strong commercial performance of CMP diagnostics in the U.S. Some of the major contributors to market growth are high disease burden, rising consumer awareness, government initiatives, technological advances, and improvements in healthcare infrastructure. In addition, key player presence is projected to bode well for CMP testing demand. Increasing number of skill CMP testing provided in North America will attribute to implementation of professional skill test for rising operational efficiency, striation regulatory compliances for new entrance in the market. North America is also a major hub for industries like pharmaceuticals, food, water & environment, commercial drinks, cosmetics, and cannabis testing. A large number of laboratories are undertaking product testing across these industries in this region.

A comprehensive metabolic panel is a group of fourteen blood tests that doctors usually order during annual physical examinations to monitor for health issues. A CMP provides a rough overview of blood sugar levels, liver and kidney function, and acid/base fluid balance & electrolytes. Patients with high blood pressure or diabetes, as well as kidney and liver damage in patients taking certain medications such as acetaminophen, statins, opioids, and antibiotics, this test are also regularly used to monitor disease progression. Factors such as increased prevalence of chronic diseases and emphasis on early diagnosis and treatment will drive demand for CMP testing. One of the factors responsible for increasing the incidence of chronic diseases is the high prevalence of lifestyle-associated diseases such as obesity coupled with unhealthy eating habits, smoking prevalence, and lack of physical activity.

In the past few years, kidney diseases held the prominent market share, fueled by a high prevalence of disease and maximum analytical utilization. Diabetes and high blood pressure are the two main causes of chronic kidney disease, responsible for up to two-thirds of cases. Diabetes occurs when your blood sugar is too high, causing damage to many organs, including kidneys, heart, and blood vessels, eyes, and nerves. High blood pressure or hypertension occurs when blood pressure on blood vessel walls increases. High blood pressure may be a leading cause of heart attacks, strokes, and chronic kidney disease if uncontrolled or poorly controlled. Chronic disease of the kidney can also cause high blood pressure.

The global comprehensive metabolic panel (CMP) testing market is highly competitive and consists of key major manufacturers. Some key market players include Sonic Healthcare, Quest Diagnostics, UNIPATH, Laboratory Corporation of America Holdings (LabCorp), Abbott, SYNLAB International GmbH and Others. Major players are focused on strategic initiatives such as product launches, fusions, development and acquisitions, licensing and co-development agreements, thus ensuring the competitiveness of this market.

Recent Developments:

  • In January 2019, Abbott acquires Cephea Valve Technologies, Inc., a private medical device company that develops a less invasive heart valve replacement technology for mitral valve disease patients. There was no disclosure of financial terms. Abbott supplied capital to buy Cephea in 2015 and secured an alternative.
  • In June 2019, the Covance Drug Development section of LabCorp finished the purchase of the non-clinical contract research services company of Envigo, increasing the worldwide non-clinical drug development capacities of Covance with extra places and resources. Envigo’s Research Models and Services business finished the Covance Research products business acquisition, leading in an organization devoted to providing a complete variety of research models, diets and bedding. Through a multi-year renewable supply contract, the two businesses will continue to work together.
  • In July 2018, SYNLAB, Europe’s major supplier of medical diagnostic services, announced that the Group has acquired 100% of the shares of Yhtyneet Medix Laboratoriot Oy, Finland’s major personal laboratory firm, from Medix Laboratoriot Oy and Yhtyneet Laboratoriot Oy.

The players profiled in the report are Sonic Healthcare, Quest Diagnostics, UNIPATH, Laboratory Corporation of America Holdings (LabCorp), Abbott, SYNLAB International GmbH and among others. Major players are focused on strategic initiatives such as product launches, fusions, development and acquisitions, licensing and co-development agreements, thus ensuring the competitiveness of this market.

Market Segmentation

Market By Disease

  • Kidney Disease
  • Liver Disease
  • Diabetes
  • Others

Market By Test Type

  • Proteins
  • Electrolytes
  • Kidney Tests
  • Liver Functional Tests
  • Glucose

Market By End-Use

  • Laboratories
  • PoC

Market By Geography

  • North America
    • US.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Would like to place an order or any question, please feel free to contact at  sales@acumenresearchandconsulting.com | +1 407 915 4157

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW
1.1. Definition and Scope
1.1.1. Definition of Comprehensive Metabolic Panel (CMP) Testing
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Comprehensive Metabolic Panel (CMP) Testing Market By Disease
1.2.2.1. Global Comprehensive Metabolic Panel (CMP) Testing Market Revenue and Growth Rate Comparison By Disease (2015-2026)
1.2.2.2. Global Comprehensive Metabolic Panel (CMP) Testing Market Revenue Share By Disease in 2018
1.2.2.3. Kidney Disease
1.2.2.4. Liver Disease
1.2.2.5. Diabetes
1.2.2.6. Others
1.2.3. Comprehensive Metabolic Panel (CMP) Testing Market By Test Type
1.2.3.1. Global Comprehensive Metabolic Panel (CMP) Testing Market Revenue and Growth Rate Comparison By Test Type (2015-2026)
1.2.3.2. Proteins
1.2.3.3. Electrolytes
1.2.3.4. Kidney Tests
1.2.3.5. Liver Functional Tests
1.2.3.6. Glucose
1.2.4. Comprehensive Metabolic Panel (CMP) Testing Market By End-Use
1.2.4.1. Global Comprehensive Metabolic Panel (CMP) Testing Market Revenue and Growth Rate Comparison By End-Use (2015-2026)
1.2.4.2. Laboratories
1.2.4.3. PoC
1.2.5. Comprehensive Metabolic Panel (CMP) Testing Market By Geography
1.2.5.1. Global Comprehensive Metabolic Panel (CMP) Testing Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.5.2. North America Comprehensive Metabolic Panel (CMP) Testing Market Revenue and Growth Rate (2015-2026)
1.2.5.3. Europe Comprehensive Metabolic Panel (CMP) Testing Market Revenue and Growth Rate (2015-2026)
1.2.5.4. Asia-Pacific Comprehensive Metabolic Panel (CMP) Testing Market Revenue and Growth Rate (2015-2026)
1.2.5.5. Latin America Comprehensive Metabolic Panel (CMP) Testing Market Revenue and Growth Rate (2015-2026)
1.2.5.6. Middle East and Africa (MEA) Comprehensive Metabolic Panel (CMP) Testing Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2018
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Comprehensive Metabolic Panel (CMP) Testing Major Manufacturers in 2018
3.2. Manufacturing Plants Distribution of Global Comprehensive Metabolic Panel (CMP) Testing Major Manufacturers in 2018
3.3. R&D Status and Technology Source of Global Comprehensive Metabolic Panel (CMP) Testing Major Manufacturers in 2018
3.4. Raw Materials Sources Analysis of Global Comprehensive Metabolic Panel (CMP) Testing Major Manufacturers in 2018

CHAPTER 4. COMPREHENSIVE METABOLIC PANEL (CMP) TESTING MARKET BY DISEASE

4.1. Global Comprehensive Metabolic Panel (CMP) Testing Revenue By Disease
4.2. Kidney Disease
4.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.3. Liver Disease
4.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.4. Diabetes
4.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.5. Others
4.5.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)

CHAPTER 5. COMPREHENSIVE METABOLIC PANEL (CMP) TESTING MARKET BY TEST TYPE

5.1. Global Comprehensive Metabolic Panel (CMP) Testing Revenue By Test Type
5.2. Proteins
5.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.3. Electrolytes
5.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.4. Kidney Tests
5.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.5. Liver Functional Tests
5.5.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.5.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.6. Glucose
5.6.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.6.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)

CHAPTER 6. COMPREHENSIVE METABOLIC PANEL (CMP) TESTING MARKET BY END-USE
6.1. Global Comprehensive Metabolic Panel (CMP) Testing Revenue By End-Use
6.2. Laboratories
6.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.3. PoC
6.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)

CHAPTER 7. NORTH AMERICA COMPREHENSIVE METABOLIC PANEL (CMP) TESTING MARKET BY COUNTRY
7.1. North America Comprehensive Metabolic Panel (CMP) Testing Market Revenue and Growth Rate, 2015 – 2026 ($Million)
7.2. North America Comprehensive Metabolic Panel (CMP) Testing Market Revenue Share Comparison, 2015 & 2026 (%)
7.3. U.S.
7.3.1. U.S. Comprehensive Metabolic Panel (CMP) Testing Market Revenue and Forecast By Disease, 2015 – 2026 ($Million)
7.3.2. Market Revenue and Forecast By Test Type, 2015 – 2026 ($Million)
7.3.3. Market Revenue and Forecast By End-Use, 2015 – 2026 ($Million)
7.4. Canada
7.4.1. Market Revenue and Forecast By Disease, 2015 – 2026 ($Million)
7.4.2. Market Revenue and Forecast By Test Type, 2015 – 2026 ($Million)
7.4.3. Market Revenue and Forecast By End-Use, 2015 – 2026 ($Million)

CHAPTER 8. EUROPE COMPREHENSIVE METABOLIC PANEL (CMP) TESTING MARKET BY COUNTRY
8.1. Europe Comprehensive Metabolic Panel (CMP) Testing Market Revenue and Growth Rate, 2015 – 2026 ($Million)
8.2. Europe Comprehensive Metabolic Panel (CMP) Testing Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. UK
8.3.1. Market Revenue and Forecast By Disease, 2015 – 2026 ($Million)
8.3.2. Market Revenue and Forecast By Test Type, 2015 – 2026 ($Million)
8.3.3. Market Revenue and Forecast By End-Use, 2015 – 2026 ($Million)
8.4. Germany
8.4.1. Market Revenue and Forecast By Disease, 2015 – 2026 ($Million)
8.4.2. Market Revenue and Forecast By Test Type, 2015 – 2026 ($Million)
8.4.3. Market Revenue and Forecast By End-Use, 2015 – 2026 ($Million)
8.5. France
8.5.1. Market Revenue and Forecast By Disease, 2015 – 2026 ($Million)
8.5.2. Market Revenue and Forecast By Test Type, 2015 – 2026 ($Million)
8.5.3. Market Revenue and Forecast By End-Use, 2015 – 2026 ($Million)
8.6. Spain
8.6.1. Market Revenue and Forecast By Disease, 2015 – 2026 ($Million)
8.6.2. Market Revenue and Forecast By Test Type, 2015 – 2026 ($Million)
8.6.3. Market Revenue and Forecast By End-Use, 2015 – 2026 ($Million)
8.7. Rest of Europe
8.7.1. Market Revenue and Forecast By Disease, 2015 – 2026 ($Million)
8.7.2. Market Revenue and Forecast By Test Type, 2015 – 2026 ($Million)
8.7.3. Market Revenue and Forecast By End-Use, 2015 – 2026 ($Million)

CHAPTER 9. ASIA-PACIFIC COMPREHENSIVE METABOLIC PANEL (CMP) TESTING MARKET BY COUNTRY
9.1. Asia-Pacific Comprehensive Metabolic Panel (CMP) Testing Market Revenue and Growth Rate, 2015 – 2026 ($Million)
9.2. Asia-Pacific Comprehensive Metabolic Panel (CMP) Testing Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. China
9.3.1. Market Revenue and Forecast By Disease, 2015 – 2026 ($Million)
9.3.2. Market Revenue and Forecast By Test Type, 2015 – 2026 ($Million)
9.3.3. Market Revenue and Forecast By End-Use, 2015 – 2026 ($Million)
9.4. Japan
9.4.1. Market Revenue and Forecast By Disease, 2015 – 2026 ($Million)
9.4.2. Market Revenue and Forecast By Test Type, 2015 – 2026 ($Million)
9.4.3. Market Revenue and Forecast By End-Use, 2015 – 2026 ($Million)
9.5. India
9.5.1. Market Revenue and Forecast By Disease, 2015 – 2026 ($Million)
9.5.2. Market Revenue and Forecast By Test Type, 2015 – 2026 ($Million)
9.5.3. Market Revenue and Forecast By End-Use, 2015 – 2026 ($Million)
9.6. Australia
9.6.1. Market Revenue and Forecast By Disease, 2015 – 2026 ($Million)
9.6.2. Market Revenue and Forecast By Test Type, 2015 – 2026 ($Million)
9.6.3. Market Revenue and Forecast By End-Use, 2015 – 2026 ($Million)
9.7. South Korea
9.7.1. Market Revenue and Forecast By Disease, 2015 – 2026 ($Million)
9.7.2. Market Revenue and Forecast By Test Type, 2015 – 2026 ($Million)
9.7.3. Market Revenue and Forecast By End-Use, 2015 – 2026 ($Million)
9.8. Rest of Asia-Pacific
9.8.1. Market Revenue and Forecast By Disease, 2015 – 2026 ($Million)
9.8.2. Market Revenue and Forecast By Test Type, 2015 – 2026 ($Million)
9.8.3. Market Revenue and Forecast By End-Use, 2015 – 2026 ($Million)

CHAPTER 10. LATIN AMERICA COMPREHENSIVE METABOLIC PANEL (CMP) TESTING MARKET BY COUNTRY
10.1. Latin America Comprehensive Metabolic Panel (CMP) Testing Market Revenue and Growth Rate, 2015 – 2026 ($Million)
10.2. Latin America Comprehensive Metabolic Panel (CMP) Testing Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. Brazil
10.3.1. Market Revenue and Forecast By Disease, 2015 – 2026 ($Million)
10.3.2. Market Revenue and Forecast By Test Type, 2015 – 2026 ($Million)
10.3.3. Market Revenue and Forecast By End-Use, 2015 – 2026 ($Million)
10.4. Mexico
10.4.1. Market Revenue and Forecast By Disease, 2015 – 2026 ($Million)
10.4.2. Market Revenue and Forecast By Test Type, 2015 – 2026 ($Million)
10.4.3. Market Revenue and Forecast By End-Use, 2015 – 2026 ($Million)
10.5. Rest of Latin America
10.5.1. Market Revenue and Forecast By Disease, 2015 – 2026 ($Million)
10.5.2. Market Revenue and Forecast By Test Type, 2015 – 2026 ($Million)
10.5.3. Market Revenue and Forecast By End-Use, 2015 – 2026 ($Million)

CHAPTER 11. MIDDLE EAST & AFRICA COMPREHENSIVE METABOLIC PANEL (CMP) TESTING MARKET BY COUNTRY
11.1. Middle East & Africa Comprehensive Metabolic Panel (CMP) Testing Market Revenue and Growth Rate, 2015 – 2026 ($Million)
11.2. Middle East & Africa Comprehensive Metabolic Panel (CMP) Testing Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. GCC
11.3.1. Market Revenue and Forecast By Disease, 2015 – 2026 ($Million)
11.3.2. Market Revenue and Forecast By Test Type, 2015 – 2026 ($Million)
11.3.3. Market Revenue and Forecast By End-Use, 2015 – 2026 ($Million)
11.4. South Africa
11.4.1. Market Revenue and Forecast By Disease, 2015 – 2026 ($Million)
11.4.2. Market Revenue and Forecast By Test Type, 2015 – 2026 ($Million)
11.4.3. Market Revenue and Forecast By End-Use, 2015 – 2026 ($Million)
11.5. Rest of Middle East & AFRICA
11.5.1. Market Revenue and Forecast By Disease, 2015 – 2026 ($Million)
11.5.2. Market Revenue and Forecast By Test Type, 2015 – 2026 ($Million)
11.5.3. Market Revenue and Forecast By End-Use, 2015 – 2026 ($Million)

CHAPTER 12. COMPANY PROFILE
12.1. Sonic Healthcare
12.1.1. Company Snapshot
12.1.2. Overview
12.1.3. Financial Overview
12.1.4. Type Portfolio
12.1.5. Key Developments
12.1.6. Strategies
12.2. Quest Diagnostics
12.2.1. Company Snapshot
12.2.2. Overview
12.2.3. Financial Overview
12.2.4. Type Portfolio
12.2.5. Key Developments
12.2.6. Strategies
12.3. UNIPATH
12.3.1. Company Snapshot
12.3.2. Overview
12.3.3. Financial Overview
12.3.4. Type Portfolio
12.3.5. Key Developments
12.3.6. Strategies
12.4. Laboratory Corporation of America Holdings (LabCorp)
12.4.1. Company Snapshot
12.4.2. Overview
12.4.3. Financial Overview
12.4.4. Type Portfolio
12.4.5. Key Developments
12.4.6. Strategies
12.5. Abbott
12.5.1. Company Snapshot
12.5.2. Overview
12.5.3. Financial Overview
12.5.4. Type Portfolio
12.5.5. Key Developments
12.5.6. Strategies
12.6. SYNLAB International GmbH
12.6.1. Company Snapshot
12.6.2. Overview
12.6.3. Financial Overview
12.6.4. Type Portfolio
12.6.5. Key Developments
12.6.6. Strategies
12.7. Others
12.7.1. Company Snapshot
12.7.2. Overview
12.7.3. Financial Overview
12.7.4. Type Portfolio
12.7.5. Key Developments
12.7.6. Strategies

CHAPTER 13. RESEARCH APPROACH
13.1. Research Methodology
13.1.1. Initial Data Search
13.1.2. Secondary Research
13.1.3. Primary Research
13.2. Assumptions and Scope

The report is readily available and can be dispatched immediately after payment confirmation.

Buy this premium research report@ https://www.acumenresearchandconsulting.com/buy-now/0/1587

About Acumen Research and Consulting:

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.

LEAVE A REPLY

Please enter your comment!
Please enter your name here